Will the new target-specific oral anticoagulants improve the treatment of venous thromboembolism?

Thrombosis and Haemostasis

Volumn 107, Issue 6, 2012, Pages 1009-1011

  Ansell, Jack ^a  

^a LENOX HILL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; DABIGATRAN ETEXILATE; EDOXABAN; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; RIVAROXABAN; WARFARIN; XIMELAGATRAN;

BLEEDING; DEEP VEIN THROMBOSIS; DRUG DOSE INCREASE; DRUG TARGETING; EDITORIAL; HEART ATRIUM FIBRILLATION; HUMAN; LUNG EMBOLISM; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; FEMALE; HUMANS; MALE; MORPHOLINES; THIOPHENES; VENOUS THROMBOEMBOLISM;

EID: 84861723060     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-02-0107     Document Type: Editorial

References (19)

1. Budnitz DS, Lovegrove MC, Shehab N, et al. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 2011; 365: 2002-2012.
2. Ogilvie IM, Newton N, Welner SA, et al. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med 2010; 123: 638-645.
3. th Ed: American College of Chest Physicians Evidence-Based Clinical Practice guidelines. Chest 2012; 141 (Suppl): e419S-e494S.
4. Kahn SR. The post-thrombotic syndrome: progress and pitfalls. Brit J Haematol 2006; 134: 357-365.
5. Becattini C, Agnelli G, Pesavento R, et al. Incidence of chronic thromboembolic pulmonary hypertension after a first episode of pulmonary embolism. Chest 2006; 130: 172-175.
6. Ansell J, Askin D. New Targets for anticoagulation and future perspectives. Curr Drug Discov Technol 2011; in press.
7. van Ryn J, Stangier J, Haertter S, et al. Dabigatran et-exilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116-1127.
8. Cohen A, Dobromirski M. The use of rivaroxaban for short- and long-term treatment of VTE. J Thromb Haemost 2012; 107: 1035-1043.
9. Schulman S, Kearon C, Kakkar AK, et al., for the RECOVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembol-ism. N Engl J Med 2009; 361: 2342-2352.
10. Schulman S, Baanstra D, Eriksson H, et al. The RE-SONATE Study group. Dabigatran vs. placebo for extended maintenance therapy of venous thromboembolism. J Thromb Haemost 2011; 9 (Suppl.2): 22 (Abstract O-MO-037)
11. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-2510.
12. Amplify Study. Available at: http://www.trialresult-scenter.org/study10328-AMPLIFY-(CV185-056).htm. Accessed February 22, 2012.
13. Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study). Available at: http://www.clinical-trials.gov/ct2/show/NCT00986154?term=NCT00986154&rank=1. Accessed February 22, 2012.
14. Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal vein thrombosis. N Engl J Med 1986; 315: 1109-1114.
15. Brandjes D P, Heijboer H, Buller HR, et al. Acenocou-marol and heparin compared with acenocoumarol alone in the initial treatment of proximal vein thrombosis. N Engl J Med 1992; 327: 1485-1489.
16. Fiessinger JN, Huisman MV, Davidson BL, et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis. J Am Med Assoc 2005; 293: 681-689.
17. Phillips KW, Ansell J. New oral anticoagulants: Will the potential advantages be achieved? Thromb Hae-most 2010; 103: 34-39.
18. Ansell J. New oral anticoagulants should not be used as first line agents to prevent thromboembol-ism in patients with atrial fibrillation. Circulation 2011; 125: 165-170.
19. Ahrens I, Lip GY, Peter K. New oral anticoagulant drugs in cardiovascular disease. Thromb Haemost 2010; 104: 49-60.